Jiangsu Hengrui Pharmaceuticals Co.,Ltd (HKG:1276)

Market Cap	409.41B +26.6%
Revenue (ttm)	37.01B +11.6%
Net Income	9.23B +18.7%
EPS	1.39 +11.8%
Shares Out	n/a
PE Ratio	44.36
Forward PE	35.78
Dividend	0.23 (0.35%)
Ex-Dividend Date	Apr 29, 2026

Volume	6,319,350
Average Volume	2,463,600
Open	65.80
Previous Close	66.05
Day's Range	65.35 - 75.95
52-Week Range	52.50 - 95.20
Beta	0.17
RSI	53.03
Earnings Date	Aug 20, 2026

About HKG:1276

Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1970
• Employees: 20,602
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1276

Financial Performance

In 2025, HKG:1276's revenue was 31.63 billion, an increase of 13.02% compared to the previous year's 27.98 billion. Earnings were 7.71 billion, an increase of 21.69%.

Financial numbers in CNY